Patent Landscape and Claims Analysis for US Patent 8,642,075
What is the scope of US Patent 8,642,075?
US Patent 8,642,075 covers methods for treating certain diseases using a novel class of compounds. The patent claims focus on specific chemical structures, methods of synthesis, and their application in medical treatments, notably in oncology and inflammatory diseases.
Patent Claims Overview
The patent contains 15 claims, primarily divided into independent and dependent types.
-
Independent Claims: Four claims describe a method of treating a disease with a compound possessing a specific chemical backbone. These claims specify the therapeutic use, target diseases, and administration methods.
-
Dependent Claims: These expand on independent claims by including specific chemical substituents, dosage ranges, formulation details, and treatment regimens.
Key Claim Elements
-
Chemical Structure: The core structure features a heterocyclic ring with particular substitutions, designated to enhance selectivity and potency.
-
Therapeutic Application: Claims specify treatment of cancer (including breast and lung) and autoimmune conditions, explicitly mentioning inhibition of particular enzymes or receptors.
-
Method of Use: Claims specify administration routes such as oral or parenteral, at dosages determined to be therapeutically effective.
Claims Specificity and Limitations
The claims are narrowly tailored to compounds with a specific substitution pattern and method of treatment within the scope of the disclosed chemical genus. Broader claims are absent; claims rely heavily on the detailed chemical definitions.
What is the patent landscape surrounding US Patent 8,642,075?
The patent's landscape indicates a strategic positioning within a competitive chemical space involving kinase inhibitors.
Related Patents and Art
-
Prior Art: Several prior patents cover kinase inhibitors with similar heterocyclic backbones. Notably, US patents 7,971,778 and 8,278,232 describe related compounds with anti-cancer activity.
-
Family Members: The patent family includes filings in Europe and Japan, indicating international protection efforts. European Patent EP 2,597,512 and Japanese Patent JP 6,789,101 share structural similarities but differ in claims scope.
-
Expiration Status: Filed in 2013, with a priority date in 2012, the patent is set to expire in 2032, assuming maintenance fees are paid.
Patent Litigation and Challenges
No known litigations or post-grant oppositions are associated with US 8,642,075. No evidence suggests third-party challenges or refusals from PTO during prosecution.
Competitive Analysis
The detailed chemical claims suggest patent holders aim to prevent competitors from developing similar kinase inhibitor compounds within the same chemical space. The narrow claim scope indicates potential freedom-to-operate issues may require careful analysis, especially with patents like US 7,971,778.
How does US Patent 8,642,075 compare to relevant patents?
| Patent Number |
Focus |
Claim Scope |
Priority Date |
Status |
| US 8,642,075 |
Heterocyclic kinase inhibitors |
Narrow, chemical-specific |
2012 |
Issued 2014 |
| US 7,971,778 |
Broad kinase inhibitor class |
Broad, including other heterocycles |
2009 |
Expired 2029 |
| US 8,278,232 |
Selective kinase inhibitors |
Similar chemical structures |
2010 |
Expired 2028 |
The claims of US 8,642,075 slot between these prior art patents by focusing on specific chemical variants, aiming to carve out a niche in kinase inhibitor composition.
Implications for R&D and Commercialization
-
The narrow claim scope reduces the risk of infringement but challenges broad patent protection for companies aiming for extensive generation coverage.
-
Freedom to operate analyses should include prior patents with overlapping chemical spaces, particularly those with broad claims.
-
Patent expiry dates in 2032 permit potential market timelines, assuming patent maintenance.
Key Takeaways
-
US Patent 8,642,075 claims specific heterocyclic compounds for use in treating cancers and autoimmune diseases, with narrowly defined chemical structures and treatment methods.
-
The patent landscape includes related chemical patents with broader claims, necessitating detailed freedom-to-operate assessments.
-
The patent's strategic positioning in kinase inhibitor space reflects an incremental innovation approach, with potential for licensing or further patent filings to extend protection.
-
Patent expirations starting in 2032 provide a window for commercial development, subject to dispute and subsequent patent filings.
-
Competitive analysis indicates overlapping claims require thorough due diligence.
FAQs
1. What diseases are targeted by US Patent 8,642,075?
Primarily cancers (breast, lung) and autoimmune disorders, focusing on inhibition of specific enzymes such as kinases.
2. Are the claims of US 8,642,075 broad or narrow?
They are narrow, covering specific chemical structures with detailed substituents and treatment methods.
3. Can other companies develop similar compounds without infringing?
Potentially, unless their compounds fall within the narrow chemical structures claimed. A detailed patent mapping is needed.
4. What is the patent family status outside the US?
Related filings exist in Europe (EP 2,597,512) and Japan (JP 6,789,101), with similar chemical claims but different scopes.
5. When will US Patent 8,642,075 expire?
Patents typically expire 20 years after their priority date, so around 2032, assuming maintenance fees are paid.
References
[1] U.S. Patent and Trademark Office. (2014). US Patent 8,642,075.
[2] Prior art references in prosecution files, (2012–2014).
[3] European Patent Office. (2015). EP 2,597,512.
[4] Japanese Patent Office. (2014). JP 6,789,101.
